Comparative in vivo and in vitro analysis of possible estrogenic effects of perfluorooctanoic acid

Pei Li Yao, David J. Ehresman, Jessica M.Caverly Rae, Shu Ching Chang, Steven R. Frame, John L. Butenhoff, Gerald L. Kennedy, Jeffrey Maurice Peters

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Previous studies suggested that perfluorooctanoate (PFOA) could activate the estrogen receptor (ER). The present study examined the hypothesis that PFOA can activate ER using an in vivo uterotrophic assay in CD-1 mice and an in vitro reporter assay. Pre-pubertal female CD-1 mice fed an estrogen-free diet from postnatal day (PND)14 through weaning on PND18 were administered 0, 0.005, 0.01, 0.02, 0.05, 0.1, or 1mg/kg PFOA or 17β-estradiol (E2, 0.5mg/kg) from PND18-20. In contrast to E2, PFOA caused no changes in the relative uterine weight, the expression of ER target genes, or the morphology of the uterus/cervix and/or vagina on PND21. Treatment of a stable human cell line containing an ER-dependent luciferase reporter construct with a broad concentration range of PFOA caused no change in ER-dependent luciferase activity; whereas E2 caused a marked increase of ER-dependent luciferase activity. These data indicate that PFOA does not activate mouse or human ER.

Original languageEnglish (US)
Pages (from-to)62-73
Number of pages12
JournalToxicology
Volume326
DOIs
StatePublished - Dec 4 2014

Fingerprint

perfluorooctanoic acid
Estrogen Receptors
Estrogens
Luciferases
Assays
Vagina
Nutrition
In Vitro Techniques
Weaning
Cervix Uteri

All Science Journal Classification (ASJC) codes

  • Toxicology

Cite this

Yao, P. L., Ehresman, D. J., Rae, J. M. C., Chang, S. C., Frame, S. R., Butenhoff, J. L., ... Peters, J. M. (2014). Comparative in vivo and in vitro analysis of possible estrogenic effects of perfluorooctanoic acid. Toxicology, 326, 62-73. https://doi.org/10.1016/j.tox.2014.10.008
Yao, Pei Li ; Ehresman, David J. ; Rae, Jessica M.Caverly ; Chang, Shu Ching ; Frame, Steven R. ; Butenhoff, John L. ; Kennedy, Gerald L. ; Peters, Jeffrey Maurice. / Comparative in vivo and in vitro analysis of possible estrogenic effects of perfluorooctanoic acid. In: Toxicology. 2014 ; Vol. 326. pp. 62-73.
@article{6cacd1d718a346dd994f5c044c0607db,
title = "Comparative in vivo and in vitro analysis of possible estrogenic effects of perfluorooctanoic acid",
abstract = "Previous studies suggested that perfluorooctanoate (PFOA) could activate the estrogen receptor (ER). The present study examined the hypothesis that PFOA can activate ER using an in vivo uterotrophic assay in CD-1 mice and an in vitro reporter assay. Pre-pubertal female CD-1 mice fed an estrogen-free diet from postnatal day (PND)14 through weaning on PND18 were administered 0, 0.005, 0.01, 0.02, 0.05, 0.1, or 1mg/kg PFOA or 17β-estradiol (E2, 0.5mg/kg) from PND18-20. In contrast to E2, PFOA caused no changes in the relative uterine weight, the expression of ER target genes, or the morphology of the uterus/cervix and/or vagina on PND21. Treatment of a stable human cell line containing an ER-dependent luciferase reporter construct with a broad concentration range of PFOA caused no change in ER-dependent luciferase activity; whereas E2 caused a marked increase of ER-dependent luciferase activity. These data indicate that PFOA does not activate mouse or human ER.",
author = "Yao, {Pei Li} and Ehresman, {David J.} and Rae, {Jessica M.Caverly} and Chang, {Shu Ching} and Frame, {Steven R.} and Butenhoff, {John L.} and Kennedy, {Gerald L.} and Peters, {Jeffrey Maurice}",
year = "2014",
month = "12",
day = "4",
doi = "10.1016/j.tox.2014.10.008",
language = "English (US)",
volume = "326",
pages = "62--73",
journal = "Toxicology",
issn = "0300-483X",
publisher = "Elsevier Ireland Ltd",

}

Yao, PL, Ehresman, DJ, Rae, JMC, Chang, SC, Frame, SR, Butenhoff, JL, Kennedy, GL & Peters, JM 2014, 'Comparative in vivo and in vitro analysis of possible estrogenic effects of perfluorooctanoic acid', Toxicology, vol. 326, pp. 62-73. https://doi.org/10.1016/j.tox.2014.10.008

Comparative in vivo and in vitro analysis of possible estrogenic effects of perfluorooctanoic acid. / Yao, Pei Li; Ehresman, David J.; Rae, Jessica M.Caverly; Chang, Shu Ching; Frame, Steven R.; Butenhoff, John L.; Kennedy, Gerald L.; Peters, Jeffrey Maurice.

In: Toxicology, Vol. 326, 04.12.2014, p. 62-73.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparative in vivo and in vitro analysis of possible estrogenic effects of perfluorooctanoic acid

AU - Yao, Pei Li

AU - Ehresman, David J.

AU - Rae, Jessica M.Caverly

AU - Chang, Shu Ching

AU - Frame, Steven R.

AU - Butenhoff, John L.

AU - Kennedy, Gerald L.

AU - Peters, Jeffrey Maurice

PY - 2014/12/4

Y1 - 2014/12/4

N2 - Previous studies suggested that perfluorooctanoate (PFOA) could activate the estrogen receptor (ER). The present study examined the hypothesis that PFOA can activate ER using an in vivo uterotrophic assay in CD-1 mice and an in vitro reporter assay. Pre-pubertal female CD-1 mice fed an estrogen-free diet from postnatal day (PND)14 through weaning on PND18 were administered 0, 0.005, 0.01, 0.02, 0.05, 0.1, or 1mg/kg PFOA or 17β-estradiol (E2, 0.5mg/kg) from PND18-20. In contrast to E2, PFOA caused no changes in the relative uterine weight, the expression of ER target genes, or the morphology of the uterus/cervix and/or vagina on PND21. Treatment of a stable human cell line containing an ER-dependent luciferase reporter construct with a broad concentration range of PFOA caused no change in ER-dependent luciferase activity; whereas E2 caused a marked increase of ER-dependent luciferase activity. These data indicate that PFOA does not activate mouse or human ER.

AB - Previous studies suggested that perfluorooctanoate (PFOA) could activate the estrogen receptor (ER). The present study examined the hypothesis that PFOA can activate ER using an in vivo uterotrophic assay in CD-1 mice and an in vitro reporter assay. Pre-pubertal female CD-1 mice fed an estrogen-free diet from postnatal day (PND)14 through weaning on PND18 were administered 0, 0.005, 0.01, 0.02, 0.05, 0.1, or 1mg/kg PFOA or 17β-estradiol (E2, 0.5mg/kg) from PND18-20. In contrast to E2, PFOA caused no changes in the relative uterine weight, the expression of ER target genes, or the morphology of the uterus/cervix and/or vagina on PND21. Treatment of a stable human cell line containing an ER-dependent luciferase reporter construct with a broad concentration range of PFOA caused no change in ER-dependent luciferase activity; whereas E2 caused a marked increase of ER-dependent luciferase activity. These data indicate that PFOA does not activate mouse or human ER.

UR - http://www.scopus.com/inward/record.url?scp=84908448136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908448136&partnerID=8YFLogxK

U2 - 10.1016/j.tox.2014.10.008

DO - 10.1016/j.tox.2014.10.008

M3 - Article

C2 - 25456267

AN - SCOPUS:84908448136

VL - 326

SP - 62

EP - 73

JO - Toxicology

JF - Toxicology

SN - 0300-483X

ER -